Apellis reports Q4 EPS 47c vs (29c) last year

Reports Q4 revenue $199.913M, consensus $199.44M. “2025 was a year of disciplined execution and meaningful progress across the business, and we enter 2026 with clear priorities and a strong foundation,” said Cedric Francois, M.D., Ph.D., chief executive officer at Apellis (APLS). “We are focused on positioning SYFOVRE for its next phase of growth, maximizing EMPAVELI’s blockbuster opportunity in rare kidney diseases, and advancing a differentiated, self-funded pipeline leveraging our deep expertise in C3 biology.”